Search
Defibrotide
go.drugbank.com/drugs/DB04932ApprovedInvestigationalIt has been shown to have antithrombotic, anti-inflammatory and anti-ischemic properties (but without associated significant systemic anticoagulant effects).
Delandistrogene moxeparvovec
go.drugbank.com/drugs/DB16802ApprovedInvestigationalDelandistrogene moxeparvovec is an adeno-associated virus vector-based gene therapy developed by Sarepta Therapeutics. … It was granted accelerated approval by the FDA on June 22, 2023, as the first gene therapy to treat Duchenne Muscular Dystrophy (DMD).
Nicorandil
go.drugbank.com/drugs/DB09220ApprovedInvestigationalWithdrawnIt is not an approved drug by FDA. It is a niacinamide derivative that induces vasodilation of arterioles and large coronary arteries by activating potassium channels.
Metharbital
go.drugbank.com/drugs/DB00463ApprovedWithdrawnMetharbital is a barbiturate anticonvulsant, similar to phenobarbital, marketed as Gemonil by Abbott Laboratories. It was patented in 1905 by Emil Fischer of Merck.
Idursulfase
go.drugbank.com/drugs/DB01271ApprovedInvestigationalIdursulfase is produced by recombinant DNA technology in a human cell line. … The enzyme contains eight asparagine-linked glycosylation sites occupied by complex oligosaccharide structures.
Alendronic acid
go.drugbank.com/drugs/DB00630ApprovedInvestigationalIt functions by preventing resorption of bone[FDA Label][A959].
Omega-3-carboxylic acids
go.drugbank.com/drugs/DB09568ApprovedWithdrawn[A25808] It was developed by AstraZeneca Pharmaceuticals and firstly approved by the FDA on May 05, 2014.[L2386] … The rest of the concentration is represented by docosapentaenoic acid and traces of some other components such as alpha-tocopherol, gelatin, glycerol, sorbitol and purified water.
Bempedoic acid
go.drugbank.com/drugs/DB11936ApprovedInvestigational[L12144,L12147] It was developed by Esperion Therapeutics Inc. and approved by the FDA on February 21, 2020. … Caused by genetic mutations or lifestyle factors, hypercholesterolemia can significantly reduce quality of life and increase the risk of mortality from cardiovascular disease.
mRNA-1345
go.drugbank.com/drugs/DB18739ApprovedInvestigationalmRNA-1345 is a nucleoside modified mRNA encoding the F-glycoprotein from RSV subtype A stabilized in its prefusion conformation. It is the primary ingredient of the RSV vaccine mRESVIA. mRESVIA was first approved in the EU and US in 2024...
Tezepelumab
go.drugbank.com/drugs/DB15090ApprovedInvestigational[L39504] Tezepelumab was also approved by the European Commission on September 19, 2022.[L44712] … It was granted FDA approval on December 17, 2021, and is currently marketed under the trademark TEZSPIRE by Amgen/AstraZeneca.